Acta Neurol Scand

1. MAHAMUD Z, Burman J, Zelano J
   Temporal trends of epilepsy in multiple sclerosis.
   Acta Neurol Scand. 2022 Jul 18. doi: 10.1111/ane.13671.
   

   >> Share

   
   

   
   Brain

2. EISSMAN JM, Dumitrescu L, Mahoney ER, Smith AN, et al
   Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease.
   Brain. 2022 May 13. pii: 6585174. doi: 10.1093.
   

   >> Share

   
   

   
   Int J Neurosci

3. KHORRAMI M, Saneipour M, Moridnia A, Shaygannejad V, et al
   Interdependency of NINJ2 gene expression and polymorphism with susceptibility and response to Interferon Beta in patients with Multiple Sclerosis.
   Int J Neurosci. 2022 Aug 1:1-9. doi: 10.1080/00207454.2022.2102979.
   

   >> Share

   
   

   
   J Neuroimmunol

4. ALOISI F, Cross AH
   MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
   J Neuroimmunol. 2022;371:577935.
   

   >> Share

   
   
5. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
   CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
   J Neuroimmunol. 2022;371:577936.
   

   >> Share

   
   

   
   J Neurol

6. KREFT KL, Robertson NP
   Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
   J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
   

   >> Share

   
   

   
   J Neurol Neurosurg Psychiatry

7. CHEN J, Diouf I, Taylor BV, Kalincik T, et al
   Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis.
   J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329223.
   

   >> Share

   
   
8. KWON S, Jung SY, Han KD, Jung JH, et al
   Risk of Parkinson's disease in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea.
   J Neurol Neurosurg Psychiatry. 2022 Jul 28. pii: jnnp-2022-329389.
   

   >> Share

   
   

   
   J Neurol Sci

9. HARIRCHIAN MH, Zahednasab H, Karampoor S
   The enigmatic role of macrophage inhibitory factor (MIF) in the pathogenesis of multiple sclerosis (MS).
   J Neurol Sci. 2022;440:120351.
   

   >> Share

   
   
10. MERMELSTEIN M, Naftali J, Wilf-Yarkoni A, Lotan I, et al
    Repeated lumbar puncture in search of oligoclonal bands - What is the yield?
    J Neurol Sci. 2022;439:120298.
    

    >> Share

    
    

    
    Mult Scler

11. TAGGE IJ, Leppert IR, Fetco D, Campbell JS, et al
    Permanent tissue damage in multiple sclerosis lesions is associated with reduced pre-lesion myelin and axon volume fractions.
    Mult Scler. 2022 Jul 28:13524585221110585. doi: 10.1177/13524585221110585.
    

    >> Share

    
    

    
    Nat Rev Neurol

12. FILIPPI M, Preziosa P
    MRI predicts cognitive training effects in multiple sclerosis.
    Nat Rev Neurol. 2022 Aug 1. pii: 10.1038/s41582-022-00701.
    

    >> Share

    
    

    
    Neurologia (Engl Ed)

13. BROCHE-PEREZ Y, Jimenez-Morales RM, Monasterio-Ramos LO, Vazquez-Gomez LA, et al
    Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting Multiple Sclerosis.
    Neurologia (Engl Ed). 2022 Jul 27. pii: S2173-5808(22)00080.
    

    >> Share

    
    

    
    Neurology

14. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    

    >> Share

    
    

    
    Rev Neurol (Paris)

15. CHEDID T, Moisset X, Clavelou P
    Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature.
    Rev Neurol (Paris). 2022 Jul 15. pii: S0035-3787(22)00639.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share